Second-Line Irinotecan, Leucovorin, and 5-Fluorouracil for Gastric Cancer Patients after Failed Docetaxel and S-1

Background. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel and S-1 with or without oxaliplatin (DS/DOS). Patients and...

Full description

Saved in:
Bibliographic Details
Published in:Gastroenterology research and practice 2016-01, Vol.2016 (2016), p.1-6
Main Authors: Kim, Min-Jeong, Song, Hunho, Kim, Jung Han, Kim, Hyeong Su, Kang, Yoon-Koo, Zang, Dae Young, Kang, Ho Suk, Lim, Hyun, Lim, Man Sup, Cho, Ji Woong, Han, Boram, Ryoo, Baek-Yeol, Ryu, Min-Hee, Jung, Joo Young, Ha, Hong Il
Format: Article
Language:English
Subjects:
Analysis
Cancer therapies
Chemotherapy
Clinical trials
Docetaxel
Dosage and administration
Drug therapy
Family medical history
Fluorouracil
Gastric cancer
Leucovorin
Medical prognosis
Medicine
Metastasis
Patient outcomes
Stomach cancer
Studies
Treatment outcome
University colleges
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel and S-1 with or without oxaliplatin (DS/DOS). Patients and Methods. We reviewed the data of patients who had previously been treated with first-line DS/DOS and received biweekly irinotecan-based chemotherapy (FOLFIRI/IFL) between October 2004 and November 2011. Results. A total of 209 cycles were administered to 35 patients, with a median of 4 (range, 1–22) cycles each. The overall response rate in 29 response-assessable patients was 17.2%, including 2 complete and 3 partial responses. The median progression-free and overall survivals were 3.81 (95% confidence interval [CI], 1.82–5.80) months and 6.24 (95% CI, 1.44–11.04) months, respectively. The major grade 3/4 toxicity was neutropenia (8.6%). Conclusion. FOLFIRI/IFL chemotherapy showed modest antitumour activity and tolerable toxicities in DS/DOS-treated MGC patients.
ISSN:1687-6121
1687-630X
DOI:10.1155/2016/6857625